Renasant Bio completed $54.5 million Seed Round funding
Sector:
Life Science
Biotech
07/10/2025
Berkeley, CA USA
Renasant Bio
completed $54.5 million Seed Round funding. Investors include
5AM Ventures (lead), Atlas Venture, OrbiMed Advisors, Qiming Venture Partners.
“ADPKD is a devastating genetic disorder that affects more than 12 million people globally and still lacks truly disease-modifying therapies,” said Emily Conley, Ph.D., chief executive officer of Renasant. “Our platform of differentiated correctors and first-in-class potentiator therapies are designed to directly address the underlying cause of ADPKD across its broad mutation spectrum, offering the potential to benefit the vast majority of patients.”
About
Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression.
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
